A Phase 2 interventional study of CP-690,550 Ointment 1 and Vehicle 1 in Psoriasis, sponsored by Pfizer. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-01-11.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one is the 15th largest by enrollment, is one of 3 that started in 2011, is one of 6 in phase 2, and was the 6th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is close to the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one is the 28th largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2011, is one of 13 in phase 2, and was the 32nd registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: CP-690,550 Ointment 1
Drug: Vehicle 1
Drug: CP-690,550 Ointment 2
Drug: Vehicle 2
2% CP-690,550 Ointment 1 twice daily for 4 weeks
Vehicle 1 twice daily for 4 weeks
2% CP-690,550 Ointment 2 twice daily for 4 weeks
Vehicle 2 twice daily for 4 weeks
Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4
Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.
Time frame: Baseline, Week 4
Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3
Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.
Time frame: Baseline, Weeks 1, 2, 3
Change From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4
Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.
Time frame: Baseline, Weeks 1, 2, 3, 4
Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response of "Clear" (0) or "Almost Clear" (1)
Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
Time frame: Week 1, 2, 3, 4
Percentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score
Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
Time frame: Week 1, 2, 3, 4
Percent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4
A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm\^2.
Time frame: Baseline, Week 1, 2, 3, 4
Itch Severity Item (ISI)
The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.
Time frame: Baseline, Week 1, 2, 3, 4
Change From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4
The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.
Time frame: Baseline, Week 1, 2, 3, 4
Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category
The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.
Time frame: Week 4
Number of Participants With Administration Site Adverse Events
An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.
Time frame: Baseline up to follow up visit (Day 36-39 after last dose of study treatment) (up to maximum of 9.5 weeks)
Number of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area
Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).
Time frame: Baseline, Week 1, 2, 3, 4
Number of Participants With Draize Score of Perilesional Skin in The Treatment Area
Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.
Time frame: Baseline, Week 1, 2, 3, 4
Change From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4
Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.
Time frame: Baseline, Week 1, 2, 3, 4
Change From Baseline in Heart Rate at Week 1, 2, 3, 4
Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.
Time frame: Baseline, Week 1, 2, 3, 4
Change From Baseline in Electrocardiogram (ECG) Findings at Week 4
A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.
Time frame: Baseline, Week 4
Change From Baseline in Hemoglobin Level at Week 2, 4
Time frame: Baseline, Week 2, 4
Change From Baseline in Platelet and Neutrophil Count at Week 2, 4
Time frame: Baseline, Week 2, 4
Change From Baseline in Creatinine Level at Week 2, 4
Time frame: Baseline, Week 2, 4
Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4
Time frame: Baseline, Week 2, 4
Plasma Concentration of CP-690,550
Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter \[ng/mL\]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.
Time frame: 0 (predose), 1, 2 and 4-9 hours postdose on Day 29 or early termination
| Milestone | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Started | 23 | 13 | 25 | 10 |
| Completed | 22 | 13 | 24 | 9 |
| Not completed | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.
| percent change | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 | -53.97 ± 29.93 | -41.01 ± 20.29 | -24.26 ± 33.43 | -17.24 ± 25.40 |
Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.
| percent change | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Change at Week 1 | -31.00 ± 28.54 | -25.59 ± 18.98 | -12.65 ± 22.19 | -6.39 ± 23.06 |
| Change at Week 2 | -46.32 ± 29.46 | -28.68 ± 20.72 | -17.26 ± 27.50 | -10.32 ± 26.53 |
| Change at Week 3 | -49.90 ± 31.92 | -33.12 ± 18.92 | -26.32 ± 32.48 | -27.92 ± 19.07 |
Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.
| units on a scale | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline: Erythema | 2.52 ± 0.59 | 2.62 ± 0.51 | 2.44 ± 0.51 | 2.50 ± 0.53 |
| Change at Week 1: Erythema | -0.53 ± 0.77 | -0.77 ± 0.73 | -0.26 ± 0.62 | -0.11 ± 0.60 |
| Change at Week 2: Erythema | -0.90 ± 0.83 | -0.83 ± 0.58 | -0.42 ± 0.72 | -0.14 ± 0.69 |
| Change at Week 3: Erythema | -0.95 ± 0.90 | -1.00 ± 0.58 | -0.57 ± 0.87 | -0.75 ± 0.71 |
| Change at Week 4: Erythema | -1.14 ± 0.83 | -1.15 ± 0.69 | -0.61 ± 0.89 | -0.44 ± 0.88 |
| Baseline: Induration | 2.52 ± 0.67 | 2.46 ± 0.52 | 2.28 ± 0.46 | 2.40 ± 0.52 |
| Change at Week 1: Induration | -0.68 ± 0.82 | -0.38 ± 0.77 | -0.17 ± 0.58 | 0.00 ± 0.50 |
| Change at Week 2: Induration | -1.05 ± 0.80 | -0.58 ± 0.79 | -0.33 ± 0.70 | -0.14 ± 0.38 |
| Change at Week 3: Induration | -1.18 ± 0.73 | -0.69 ± 0.63 | -0.57 ± 0.81 | -0.38 ± 0.74 |
| Change at Week 4: Induration | -1.27 ± 0.70 | -0.92 ± 0.64 | -0.43 ± 0.90 | -0.22 ± 0.67 |
| Baseline: Scaling | 2.17 ± 0.65 | 2.23 ± 0.60 | 2.08 ± 0.49 | 2.30 ± 0.82 |
| Change at Week 1: Scaling | -0.95 ± 0.85 | -0.69 ± 0.48 | -0.48 ± 0.95 | -0.33 ± 0.71 |
| Change at Week 2: Scaling | -1.24 ± 0.83 | -0.75 ± 0.75 | -0.38 ± 0.77 | -0.43 ± 0.79 |
| Change at Week 3: Scaling | -1.27 ± 0.88 | -0.85 ± 0.99 | -0.67 ± 1.02 | -0.75 ± 0.71 |
| Change at Week 4: Scaling | -1.32 ± 0.89 | -1.00 ± 0.91 | -0.61 ± 1.03 | -0.56 ± 0.88 |
Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
| percentage of participants | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Week 1 | 42.11 | 23.08 | 21.74 | 11.11 |
| Week 2 | 52.38 | 33.33 | 29.17 | 28.57 |
| Week 3 | 59.09 | 23.08 | 38.10 | 37.50 |
| Week 4 | 63.64 | 61.54 | 39.13 | 22.22 |
Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
| percentage of participants | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Week 1 | 15.79 | 0.00 | 0.00 | 0.00 |
| Week 2 | 28.57 | 8.33 | 0.00 | 0.00 |
| Week 3 | 31.82 | 15.38 | 9.52 | 0.00 |
| Week 4 | 36.36 | 23.08 | 17.39 | 0.00 |
A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm\^2.
| percent change | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Change at Week 1 | -14.26 ± 34.86 | -11.26 ± 28.55 | -3.72 ± 19.18 | -3.50 ± 7.32 |
| Change at Week 2 | -22.67 ± 40.18 | -8.35 ± 37.19 | -5.52 ± 22.82 | -18.72 ± 22.18 |
| Change at Week 3 | -36.21 ± 42.22 | -13.52 ± 42.92 | -4.90 ± 30.23 | -13.59 ± 38.56 |
| Change at Week 4 | -38.39 ± 43.76 | -19.61 ± 49.93 | -8.71 ± 31.23 | -4.98 ± 27.05 |
The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.
| units on a scale | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline | 4.09 ± 2.52 | 5.54 ± 3.10 | 4.36 ± 2.53 | 6.20 ± 2.62 |
| Week 1 | 2.63 ± 2.54 | 4.69 ± 3.45 | 3.52 ± 2.74 | 4.22 ± 3.31 |
| Week 2 | 2.24 ± 2.23 | 3.92 ± 3.12 | 3.42 ± 2.57 | 4.71 ± 3.15 |
| Week 3 | 2.32 ± 2.42 | 3.69 ± 3.30 | 2.86 ± 2.59 | 3.50 ± 3.02 |
| Week 4 | 1.55 ± 2.04 | 3.38 ± 2.90 | 2.30 ± 2.20 | 4.44 ± 2.88 |
The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.
| units on a scale | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Change at Week 1 | -1.47 ± 2.04 | -0.85 ± 1.63 | -0.74 ± 2.22 | -2.00 ± 3.74 |
| Change at Week 2 | -1.90 ± 2.14 | -1.83 ± 3.24 | -1.00 ± 2.38 | -1.43 ± 3.87 |
| Change at Week 3 | -1.86 ± 1.91 | -1.85 ± 2.79 | -1.62 ± 2.65 | -2.75 ± 4.17 |
| Change at Week 4 | -2.64 ± 1.97 | -2.15 ± 2.85 | -2.13 ± 2.65 | -1.78 ± 3.87 |
The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.
| percentage of participants | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Very Satisfied | 50.0 | 23.1 | 32.0 | 0.0 |
| Somewhat Satisfied | 18.2 | 38.5 | 20.0 | 11.1 |
| Slightly Satisfied | 4.5 | 0 | 12.0 | 11.1 |
| Neither Satisfied nor Dissatisfied | 13.6 | 15.4 | 4.0 | 11.1 |
| Slightly Dissatisfied | 0 | 0 | 4.0 | 0 |
| Somewhat Dissatisfied | 4.5 | 7.7 | 12.0 | 22.2 |
| Very Dissatisfied | 9.1 | 15.4 | 16.0 | 44.4 |
An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.
| Participants | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Number of Participants With Administration Site Adverse Events | 1 | 0 | 0 | 0 |
Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).
| Participants | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline: None, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Baseline: Mild, Immediate Stinging/Burning | 1 | 0 | 2 | 1 |
| Baseline: Moderate, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Baseline: Severe, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Baseline: None, Persistent Stinging/Burning | 0 | 0 | 1 | 0 |
| Baseline: Mild, Persistent Stinging/Burning | 1 | 0 | 1 | 1 |
| Baseline: Moderate, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Baseline: Severe, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 1: None, Immediate Stinging/Burning | 0 | 0 | 0 | 1 |
| Week 1: Mild, Immediate Stinging/Burning | 1 | 2 | 0 | 0 |
| Week 1: Moderate, Immediate Stinging/Burning | 0 | 1 | 0 | 0 |
| Week 1: Severe, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 2: None, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 2: Mild, Immediate Stinging/Burning | 1 | 0 | 1 | 2 |
| Week 2: Moderate, Immediate Stinging/Burning | 0 | 0 | 0 | 1 |
| Week 2: Severe, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 3: None, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 3: Mild, Immediate Stinging/Burning | 1 | 0 | 1 | 0 |
| Week 3: Moderate, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 3: Severe, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 4: None, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 4: Mild, Immediate Stinging/Burning | 1 | 0 | 0 | 0 |
| Week 4: Moderate, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 4: Severe, Immediate Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 1: None, Persistent Stinging/Burning | 1 | 2 | 0 | 0 |
| Week 1: Mild, Persistent Stinging/Burning | 0 | 1 | 0 | 0 |
| Week 1: Moderate, Persistent Stinging/Burning | 0 | 0 | 0 | 1 |
| Week 1: Severe, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 2: None, Persistent Stinging/Burning | 1 | 0 | 1 | 2 |
| Week 2: Mild, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 2: Moderate, Persistent Stinging/Burning | 0 | 0 | 0 | 1 |
| Week 2: Severe, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 3: None, Persistent Stinging/Burning | 1 | 0 | 1 | 0 |
| Week 3: Mild, Persistent Stinging/Burning | 0 | 0 | 1 | 0 |
| Week 3: Moderate, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 3: Severe, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 4: None, Persistent Stinging/Burning | 1 | 0 | 0 | 0 |
| Week 4: Mild, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 4: Moderate, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
| Week 4: Severe, Persistent Stinging/Burning | 0 | 0 | 0 | 0 |
Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.
| Participants | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline, Erythema: Moderate Reaction | 0 | 0 | 1 | 0 |
| Baseline, Letter Grade: Burning, Stinging, Itching | 2 | 2 | 2 | 0 |
| Baseline,Superficial Observation:Hyperpigmentation | 0 | 0 | 1 | 0 |
| Baseline,Superficial Observation: Scaling-Flacking | 0 | 0 | 2 | 1 |
| Baseline, Superficial Observation: Glazing | 0 | 0 | 1 | 0 |
| Week 1, Erythema: Trace Reaction | 0 | 0 | 1 | 0 |
| Week 1, Erythema: Moderate Reaction | 0 | 0 | 1 | 0 |
| Week 1, Letter Grade: Burning, Stinging, Itching | 1 | 0 | 0 | 0 |
| Week 1, Superficial Observation: Peeling | 1 | 0 | 0 | 0 |
| Week 1, Superficial Observation: Scaling-Flacking | 0 | 0 | 2 | 0 |
| Week 2, Erythema: Trace Reaction | 0 | 0 | 2 | 0 |
| Week 2, Letter Grade: Burning, Stinging, Itching | 0 | 1 | 0 | 0 |
| Week 2, Superficial Observation: Scaling-Flacking | 0 | 0 | 1 | 0 |
| Week 3, Erythema: Trace Reaction | 1 | 0 | 0 | 0 |
| Week 3, Letter Grade: Burning, Stinging, Itching | 0 | 0 | 2 | 0 |
| Week 4, Superficial Observation: Hyperpigmentation | 1 | 0 | 0 | 0 |
Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.
| mmHg | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline: Diastolic BP | 77.91 ± 9.87 | 74.81 ± 9.67 | 75.52 ± 8.63 | 76.60 ± 10.86 |
| Change at Week 1: Diastolic BP | -3.18 ± 7.24 | -2.04 ± 7.17 | -2.54 ± 8.32 | -1.94 ± 7.28 |
| Change at Week 2: Diastolic BP | -1.86 ± 7.41 | -2.25 ± 5.89 | -3.63 ± 9.50 | 0.29 ± 5.80 |
| Change at Week 3: Diastolic BP | -2.23 ± 8.09 | -3.81 ± 9.04 | -0.26 ± 8.64 | -2.13 ± 8.70 |
| Change at Week 4: Diastolic BP | -2.16 ± 7.97 | -1.31 ± 6.94 | -2.61 ± 7.28 | -1.06 ± 6.58 |
| Baseline: Systolic BP | 120.57 ± 14.83 | 115.42 ± 12.77 | 125.62 ± 16.26 | 116.05 ± 15.85 |
| Change at Week 1: Systolic BP | -2.29 ± 8.48 | 3.58 ± 8.76 | -2.85 ± 8.20 | 3.39 ± 7.33 |
| Change at Week 2: Systolic BP | -2.24 ± 12.99 | 0.33 ± 7.24 | -3.67 ± 8.96 | -3.07 ± 5.99 |
| Change at Week 3: Systolic BP | -0.73 ± 12.14 | 0.65 ± 9.29 | 0.67 ± 8.62 | -0.81 ± 11.24 |
| Change at Week 4: Systolic BP | -0.55 ± 10.42 | 2.96 ± 9.73 | -5.07 ± 9.04 | 1.06 ± 9.33 |
Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.
| beats per minute | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline | 67.24 ± 10.64 | 66.77 ± 6.24 | 66.12 ± 6.82 | 73.75 ± 8.54 |
| Change at Week 1 | 2.21 ± 9.29 | 3.12 ± 9.98 | 2.28 ± 8.31 | 6.39 ± 8.66 |
| Change at Week 2 | 2.95 ± 10.75 | 2.71 ± 6.18 | 2.04 ± 7.91 | 0.36 ± 4.41 |
| Change at Week 3 | 0.61 ± 7.96 | 2.27 ± 8.76 | 4.45 ± 12.41 | 2.50 ± 3.92 |
| Change at Week 4 | 2.39 ± 7.73 | 2.85 ± 10.60 | 0.63 ± 7.08 | -2.00 ± 3.50 |
A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.
| milliseconds (msec) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline: RR Interval | 984.7 ± 165.17 | 958.4 ± 120.78 | 962.3 ± 111.02 | 887.9 ± 124.81 |
| Change at Week 4: RR Interval | -47.7 ± 80.50 | -21.5 ± 114.31 | -23.1 ± 107.99 | -8.8 ± 78.53 |
| Baseline: PR Interval | 165.3 ± 19.80 | 163.8 ± 26.10 | 159.0 ± 22.27 | 170.4 ± 20.70 |
| Change at Week 4: PR Interval | -3.5 ± 11.89 | 2.0 ± 10.41 | 1.7 ± 16.73 | 4.2 ± 11.90 |
| Baseline: QRS Complex | 92.8 ± 5.94 | 93.8 ± 9.78 | 95.3 ± 8.38 | 93.0 ± 5.83 |
| Change at Week 4: QRS Complex | -1.5 ± 7.33 | -2.8 ± 9.11 | -1.3 ± 7.11 | -0.3 ± 9.45 |
| Baseline: QT Interval | 400.2 ± 21.45 | 400.1 ± 26.91 | 411.1 ± 26.46 | 392.3 ± 19.02 |
| Change at Week 4: QT Interval | -2.7 ± 11.40 | -1.2 ± 22.42 | -8.1 ± 27.36 | 2.9 ± 16.04 |
| Baseline: QTcB Interval | 406.3 ± 24.59 | 409.8 ± 18.53 | 420.1 ± 19.96 | 418.6 ± 26.88 |
| Change at Week 4: QTcB Interval | 7.1 ± 16.83 | 5.8 ± 15.03 | -2.9 ± 19.77 | 5.4 ± 16.80 |
| Baseline: QTcF Interval | 404.0 ± 17.23 | 406.5 ± 18.16 | 417.0 ± 19.39 | 409.6 ± 20.03 |
| Change at Week 4: QTcF Interval | 3.6 ± 12.88 | 3.0 ± 12.86 | -4.8 ± 19.62 | 4.3 ± 14.34 |
| grams per deciliter (g/dL) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline | 14.56 ± 1.34 | 13.68 ± 1.41 | 14.21 ± 1.26 | 13.90 ± 1.29 |
| Change at Week 2 | -0.20 ± 0.59 | 0.12 ± 0.48 | 0.19 ± 0.52 | -0.06 ± 0.35 |
| Change at Week 4 | -0.01 ± 0.56 | -0.08 ± 0.66 | -0.02 ± 0.49 | -0.09 ± 0.39 |
| 10^3 per cubic millimeter (10^3/mm^3) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline: Platelet | 227.30 ± 69.97 | 212.85 ± 58.76 | 233.68 ± 50.79 | 214.90 ± 58.67 |
| Change at Week 2: Platelet | 6.38 ± 20.88 | 6.85 ± 28.31 | 0.00 ± 21.37 | 13.00 ± 15.68 |
| Change at Week 4: Platelet | 1.05 ± 13.88 | -2.46 ± 15.33 | -7.30 ± 23.07 | 2.50 ± 12.65 |
| Baseline: Neutrophil | 3.87 ± 1.36 | 3.75 ± 1.06 | 4.71 ± 1.04 | 3.79 ± 1.48 |
| Change at Week 2: Neutrophil | 0.00 ± 0.59 | 0.00 ± 0.57 | 0.06 ± 0.88 | 0.23 ± 0.51 |
| Change at Week 4: Neutrophil | -0.01 ± 0.77 | -0.21 ± 0.41 | -0.34 ± 0.94 | 0.01 ± 0.57 |
| milligram per deciliter (mg/dL) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline | 1.00 ± 0.22 | 0.89 ± 0.19 | 0.93 ± 0.14 | 0.89 ± 0.17 |
| Change at Week 2 | -0.02 ± 0.06 | -0.01 ± 0.06 | 0.03 ± 0.07 | -0.04 ± 0.09 |
| Change at Week 4 | -0.01 ± 0.06 | -0.01 ± 0.07 | -0.02 ± 0.07 | -0.00 ± 0.05 |
| international unit per liter (IU/L) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| Baseline: AST | 24.57 ± 12.35 | 22.77 ± 6.69 | 23.04 ± 14.04 | 21.10 ± 5.38 |
| Change at Week 2: AST | -2.00 ± 7.46 | -1.23 ± 3.83 | 1.84 ± 4.59 | -2.00 ± 3.57 |
| Change at Week 4: AST | -2.29 ± 7.18 | -1.08 ± 3.09 | 0.70 ± 5.98 | 0.63 ± 3.46 |
| Baseline: ALT | 32.22 ± 26.77 | 28.08 ± 16.01 | 24.28 ± 17.81 | 27.60 ± 13.37 |
| Change at Week 2: ALT | -4.48 ± 14.88 | -3.54 ± 4.77 | 2.12 ± 4.75 | -0.67 ± 7.00 |
| Change at Week 4: ALT | -5.76 ± 17.67 | -3.23 ± 5.45 | 0.61 ± 5.75 | -0.13 ± 1.96 |
| Baseline: CK | 117.91 ± 67.38 | 106.62 ± 73.11 | 100.16 ± 61.20 | 93.10 ± 32.29 |
| Change at Week 2: CK | -1.05 ± 40.05 | -11.00 ± 17.88 | 13.00 ± 47.55 | 8.00 ± 56.44 |
| Change at Week 4: CK | 4.14 ± 49.49 | 19.62 ± 73.16 | -2.13 ± 25.91 | -6.88 ± 22.25 |
Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter \[ng/mL\]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.
| ng/mL | 2% CP-690,550 Ointment 1 | 2% CP-690,550 Ointment 2 |
|---|---|---|
| 0 hours | 0.1336 ± 0.1499 | 0.0313 ± 0.0742 |
| 1 hour | 0.1522 ± 0.1839 | 0.0434 ± 0.1083 |
| 2 hours | 0.1548 ± 0.2089 | 0.0570 ± 0.1459 |
| 4 hours | 0.1514 ± 0.2244 | 0.0553 ± 0.1420 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2% CP-690,550 Ointment 1 | — | 0/23 (0%) | 10/23 (43.5%) |
| Vehicle 1 | — | 0/13 (0%) | 3/13 (23.1%) |
| 2% CP-690,550 Ointment 2 | — | 0/25 (0%) | 9/25 (36%) |
| Vehicle 2 | — | 0/10 (0%) | 3/10 (30%) |
| Event | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/23 | 0/13 | 2/25 | 1/10 |
| PharyngitisInfections and infestations | 0/23 | 0/13 | 0/25 | 1/10 |
| TonsillitisInfections and infestations | 0/23 | 0/13 | 0/25 | 1/10 |
| Muscle strainInjury, poisoning and procedural complications | 0/23 | 0/13 | 0/25 | 1/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/23 | 0/13 | 0/25 | 1/10 |
| Urinary tract infectionInfections and infestations | 1/23 | 1/13 | 0/25 | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/23 | 1/13 | 0/25 | 0/10 |
| PresyncopeNervous system disorders | 0/23 | 1/13 | 0/25 | 0/10 |
| DyspepsiaGastrointestinal disorders | 1/23 | 0/13 | 0/25 | 0/10 |
| Application site erythemaGeneral disorders | 1/23 | 0/13 | 0/25 | 0/10 |
| Age, Customized(Participants) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 | Total |
|---|---|---|---|---|---|
| 18 to 44 years | 7 | 5 | 5 | 4 | 21 |
| 45 to 64 years | 12 | 5 | 13 | 6 | 36 |
| Greater than or equal to 65 years | 4 | 3 | 7 | 0 | 14 |
| Sex: Female, Male(Participants) | 2% CP-690,550 Ointment 1 | Vehicle 1 | 2% CP-690,550 Ointment 2 | Vehicle 2 | Total |
|---|---|---|---|---|---|
| Female | 6 | 8 | 10 | 4 | 28 |
| Male | 17 | 5 | 15 | 6 | 43 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2011 to primary completion in Nov 2011, 9 months.
Results were first posted in Jan 2021, 9 years 1 month after primary completion. A results delay was requested in Apr 2013.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib